Literature DB >> 21993386

A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide.

R K Gupta1, A N Ezeonyeji, A S Thomas, M A Scully, M R Ehrenstein, D A Isenberg.   

Abstract

Pure red cell aplasia (PRCA) is a recognized but rare complication of systemic lupus erythematosus (SLE) and is characterized by the near absence of red blood cell precursors in the bone marrow but with normal megakaryocyte and granulocytes. We report a novel case of acquired PRCA occurring simultaneously with immune thrombocytopenia in the context of active SLE. Both syndromes were refractory to conventional treatment but responded to rituximab and cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993386     DOI: 10.1177/0961203311411349

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

1.  Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia.

Authors:  Xuemei Wu; Lang Cheng; Xiaoqing Liu; Yu Sun; Bingzong Li; Guangsheng He; Jianyong Li
Journal:  Ann Hematol       Date:  2022-04-23       Impact factor: 3.673

2.  Outcomes of rituximab therapy in refractory lupus: A meta-analysis.

Authors:  Fatma Alshaiki; Elaf Obaid; Abdulqader Almuallim; Rabab Taha; Hadeel El-Haddad; Hani Almoallim
Journal:  Eur J Rheumatol       Date:  2018-02-13

3.  Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab.

Authors:  Andrea Tendas; Pasquale Niscola; Laura Scaramucci; Luca Cupelli; Alessio Pio Perrotti; Paolo de Fabritiis
Journal:  Blood Res       Date:  2016-06-23

Review 4.  Lupus thrombocytopenia: pathogenesis and therapeutic implications.

Authors:  Nikolaos Galanopoulos; Anna Christoforidou; Zoe Bezirgiannidou
Journal:  Mediterr J Rheumatol       Date:  2017-03-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.